RxDoctor Payments Data

Jordan Ahnert

Cardiovascular Disease · Brunswick, GANPI 1124500939

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,947 of the $2,372 with a category attached, or 82.1%. Amgen accounts for 82.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $1,981 and has fallen 96.2% since, to $75 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in GA, where the typical reported total is $2,276.

$2,372in general payments, 2019–2025

Across 22 payments — averaging $107.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Ambu Inc.$45
  • Boston Scientific$45
  • Davol Inc.$39
  • Endomagnetics Ltd$38
  • Bard Peripheral Vascular, Inc.$36
  • plus $223 from 12 others
$600,874in research payments, 2019–2025

Across 25 payments — averaging $24,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beone Medicines AUS Pty Ltd$277K
  • Beigene AUS Pty Ltd$161K
  • Astrazeneca UK Limited$107K
  • AstraZeneca$55K
  • Incyte Corporation$1K

What the payments were for

  • Consulting fees$1,94782%
  • Food & beverage$42518%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,372 in reported general payments places this provider in the 50th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia →

Other cardiovascular disease in Brunswick

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →